A brief history of calcitonin

Lancet

Volumn 359, Issue 9309, 2002, Pages 885-886

  Colman, Eric ^a   Hedin, Randy ^a   Swann, Joslyn ^a   Orloff, David ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCITONIN; ETIDRONIC ACID; FLUORIDE; RALOXIFENE; RISEDRONIC ACID; SALCATONIN;

BONE; BONE DENSITY; BONE MINERAL; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; FRACTURE; HUMAN; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; SHORT SURVEY; VERTEBRA FRACTURE;

EID: 0037045859     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)07949-7     Document Type: Note

References (19)

1. Evidence for calcitonin - A new hormone from the parathyroid that lowers blood calcium
2. Thyrocalcitonin, inhibitor of bone resorption in tissue culture
3. Calcium metabolism and calcium kinetics before and long term thyrocalcitonin treatment in senile osteoporosis
4. Effects of porcine calcitonin on calcium metabolism in osteoporosis
5. Long-term calcitonin therapy in postmenopausal osteoporosis
6. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis
7. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture
8. A double-blind placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss
9. A double-blind study of intranasal calcitonin for established postmenopausal osteoporosis
10. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Reocurrence of Osteoporotic Fractures study
11. What PROOF proves about calcitonin and clinical trials
12. Osteoporosis prevention, diagnosis, and therapy